WuXi AppTec Co. Ltd (WX8) - Total Liabilities

Latest as of March 2026: €22.64 Billion EUR ≈ $26.47 Billion USD

Based on the latest financial reports, WuXi AppTec Co. Ltd (WX8) has total liabilities worth €22.64 Billion EUR (≈ $26.47 Billion USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check WuXi AppTec Co. Ltd (WX8) asset resilience to evaluate the company's liquid asset resilience ratio.

WuXi AppTec Co. Ltd - Total Liabilities Trend (2016–2025)

This chart illustrates how WuXi AppTec Co. Ltd's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see WuXi AppTec Co. Ltd (WX8) total assets.

WuXi AppTec Co. Ltd Competitors by Total Liabilities

The table below lists competitors of WuXi AppTec Co. Ltd ranked by their total liabilities.

Company Country Total Liabilities
Onto Innovation Inc
NYSE:ONTO
USA $264.18 Million
Azrieli Group Ltd
TA:AZRG
Israel ILA38.26 Billion
Albemarle Corp
NYSE:ALB
USA $5.03 Billion
QXO, Inc.
NYSE:QXO
USA $6.50 Billion
Globe Life Inc
NYSE:GL
USA $25.41 Billion
SPIC Dongfang New Energy Corp
SHE:000958
China CN¥85.34 Billion
Formosa Plastics Corp
TW:1301
Taiwan NT$197.52 Billion
Neurocrine Biosciences Inc
NASDAQ:NBIX
USA $1.38 Billion

Liability Composition Analysis (2016–2025)

This chart breaks down WuXi AppTec Co. Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See how leveraged is WuXi AppTec Co. Ltd's balance sheet to measure how much of total assets are equity-financed.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric Value Description
Current Ratio 3.42 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity 0.27 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 0.21 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how WuXi AppTec Co. Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for WuXi AppTec Co. Ltd (2016–2025)

The table below shows the annual total liabilities of WuXi AppTec Co. Ltd from 2016 to 2025.

Year Total Liabilities Change
2025-12-31 €22.87 Billion
≈ $26.74 Billion
+7.69%
2024-12-31 €21.24 Billion
≈ $24.83 Billion
+17.01%
2023-12-31 €18.15 Billion
≈ $21.22 Billion
+2.19%
2022-12-31 €17.76 Billion
≈ $20.77 Billion
+8.51%
2021-12-31 €16.37 Billion
≈ $19.14 Billion
+20.61%
2020-12-31 €13.57 Billion
≈ $15.87 Billion
+14.74%
2019-12-31 €11.83 Billion
≈ $13.83 Billion
+162.76%
2018-12-31 €4.50 Billion
≈ $5.26 Billion
-22.94%
2017-12-31 €5.84 Billion
≈ $6.83 Billion
+29.02%
2016-12-31 €4.53 Billion
≈ $5.29 Billion
--

About WuXi AppTec Co. Ltd

F:WX8 Germany Diagnostics & Research
Market Cap
$13.06 Billion
€11.17 Billion EUR
Market Cap Rank
#1818 Global
#383 in Germany
Share Price
€21.88
Change (1 day)
+0.05%
52-Week Range
€10.60 - €22.37
All Time High
€22.37
About

WuXi AppTec Co., Ltd., an investment holding company, provides research and manufacturing services to discover, develop, and manufacture spectrum for small molecule drugs in the People's Republic of China, the United States, Europe, and internationally. The company operates through WuXi Chemistry, WuXi Testing, WuXi Biology, and Others segments. It offers contract research, development, and manuf… Read more